Sanofi Appoints Chris Corsico as New Global Development Head, Strengthening R&D Leadership ###
Appointment and Role:
Sanofi has recruited Chris Corsico, formerly the head of development at GlaxoSmithKline (GSK), as its new global head of development. Corsico replaces Dietmar Berger, who left Sanofi for a role at Gilead6.
Strategic Focus:
Corsico is expected to leverage his expertise to focus on patient-centered, data, and technology-driven pharmaceutical development8. This appointment underscores Sanofi's commitment to strengthening its R&D capabilities6.
Professional Background: Corsico has an extensive career in healthcare and pharmaceuticals:
Previously served as the head of development at GSK, where he oversaw their pharmaceutical pipeline from Phase IIa through approval, excluding oncology5.
Worked at Boehringer Ingelheim for over 20 years in multiple leadership roles, including Global Head of Medicine and Chief Medical Officer56.
Educational Credentials:
Corsico holds a medical degree from Cornell University and a Master of Public Health (MPH) from Yale University. He trained in internal medicine at Johns Hopkins University and has held academic positions prior to transitioning into the industry5.
Significance for Sanofi:
The hire signifies Sanofi's continued focus on bolstering its R&D efforts to drive innovation and competitive growth in the pharmaceutical sector6.
Sources:
5. https://www.transceleratebiopharmainc.com/leaders/christopher-corsico/
6. https://endpts.com/sanofi-continues-its-bet-on-rd-by-poaching-gsks-head-of-development/